Education
About Us
Working with TipRanks
Follow Us
Anavex Life Sciences (AVXL)
NASDAQ:AVXL
Top Page
Anavex Life Sciences
(NASDAQ:AVXL)
Select Model
Select Model
Rating:62Neutral
Price Target:―
Anavex Life Sciences receives a moderate score due to its strong balance sheet and promising technical indicators, despite the lack of current revenue and net losses. The positive momentum in clinical trials and a solid cash position are significant strengths, although valuation challenges and project delays need consideration.
Positive Factors
Strong Balance Sheet
A strong balance sheet with no debt enhances financial stability, providing flexibility to invest in R&D and withstand market fluctuations.
Promising Clinical Trial Results
Positive trial results for blarcamesine bolster Anavex's potential to bring effective Alzheimer's treatments to market, supporting long-term revenue prospects.
New Patent Issuance
The new patent strengthens Anavex's intellectual property portfolio, offering long-term protection and competitive advantage in neurodegenerative disorder treatments.
Negative Factors
Consistent Net Losses
Ongoing net losses highlight financial sustainability risks, as the company relies heavily on future revenue generation from its biotech projects.
Increased Expenses
Rising expenses, particularly in R&D, may strain cash reserves and delay profitability, impacting Anavex's ability to sustain operations without additional funding.
Regulatory and Market Uncertainty
Uncertainty in regulatory approvals and market strategies could delay product launches, affecting Anavex's ability to generate revenue and achieve market penetration.
Anavex Life Sciences (AVXL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$367.22M
Dividend YieldN/A
Average Volume (3M)3.46M
Price to Earnings (P/E)―
Beta (1Y)1.59
Revenue GrowthN/A
EPS Growth-5.71%
CountryUS
Employees42
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.11
Shares Outstanding89,348,110
10 Day Avg. Volume2,286,251
30 Day Avg. Volume3,457,673
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)8.00
Price to Sales (P/S)0.00
P/FCF Ratio-19.44
Enterprise Value/Market Cap1.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-11.47
Forecast
1Y Price Target
$20.00Price Target Upside397.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.52
Revenue Forecast (FY)$221.71M
Anavex Life Sciences Business Overview & Revenue Model
Company DescriptionAnavex Life Sciences Corp. is a clinical-stage biopharmaceutical company dedicated to the development of novel drug candidates to treat central nervous system (CNS) diseases. The company is primarily focused on developing therapies for Alzheimer's disease, Parkinson's disease, and other neurodegenerative and neurodevelopmental disorders. Anavex's lead compound, ANAVEX2-73 (blarcamesine), is being studied for its potential to modify disease progression and improve symptoms in these conditions.
How the Company Makes MoneyAnavex Life Sciences makes money primarily through the development and commercialization of its drug candidates. The company's revenue model hinges on successfully advancing its drug pipeline through clinical trials and obtaining regulatory approvals. Once approved, Anavex can generate revenue through the sale of its drugs to healthcare providers and patients. Additionally, the company may enter into partnerships or licensing agreements with larger pharmaceutical companies to co-develop or market its compounds, which can provide upfront payments, milestone payments, and royalties from sales. However, as a clinical-stage company, Anavex may not yet have significant revenue from product sales until its drugs are approved and commercially available.
Anavex Life Sciences Earnings Call Summary
Earnings Call Date:Nov 25, 2025
(Q4-2025)
| % Change Since: |
Next Earnings Date:Feb 05, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mix of positive advancements in clinical trials and strong financial positioning, contrasted by the setback of a negative CHMP opinion in Europe for blarcamesine and a decrease in R&D spending. Despite the challenges, the company remains optimistic about its scientific data and future regulatory discussions.Q4-2025 Updates
Positive Updates
Positive Clinical Data for Blarcamesine
The Phase 2b/3 trial demonstrated significant cognitive benefits in Alzheimer's patients, with patients showing less cognitive decline compared to a control group over 48 and 96 weeks. The defined precision medicine population exhibited a significant clinical improvement.
Successful Phase 2 Trial for ANAVEX 3-71
ANAVEX 3-71 showed positive results in a Phase 2 trial for schizophrenia, achieving its primary endpoint of safety and tolerability, with no serious adverse events reported.
Strong Financial Position
Anavex reported a cash position of $120 million as of September 30, 2025, with a cash runway of more than three years, and no debt.
Scientific Publications and Presentations
Anavex announced several scientific publications, including studies on blarcamesine's effects on memory impairment and brain oxidative injury, and plans to present additional data at upcoming conferences.
Negative Updates
Negative CHMP Opinion on Blarcamesine
The CHMP is expected to adopt a negative opinion on the MAA for blarcamesine in Europe, prompting Anavex to request a reexamination.
Decreased R&D Expenditure
Research and development expenses decreased to $7.3 million from $11.6 million in the comparable quarter of last year, attributed to the completion of a large manufacturing campaign and clinical trial activities.
Net Loss for the Quarter
Anavex reported a net loss of $9.8 million for the quarter, equivalent to $0.11 per share.
Company Guidance
During the Anavex Life Sciences Fiscal 2025 Fourth Quarter Conference Call, the company provided several key metrics and forward-looking statements. Anavex highlighted its commitment to advancing its clinical trials for oral blarcamesine and ANAVEX 3-71, with particular focus on regulatory actions and strategic partnerships. The company noted that the CHMP in Europe is expected to adopt a negative opinion on the MAA for blarcamesine, but Anavex plans to request a reexamination. They have successfully undergone a GCP inspection of trial data by the EMA, and the manufacturing package has passed EMA review. Anavex reported initial contacts with U.S. authorities regarding their Alzheimer's program, with updates to follow. For blarcamesine, long-term benefits were observed, with a significant difference in mean change from baseline in the ADAS-cog 13 total score, translating into 17.8 months of extended patient independence. ANAVEX 3-71 demonstrated safety and promising trends in a Phase 2 study for schizophrenia, with potential for depression treatment in Alzheimer's disease. Financially, Anavex reported a cash position of $102.6 million as of September 30, 2025, with no debt and a cash runway exceeding three years. Research and development expenses were $7.3 million for the quarter, while general and administrative expenses were $3.5 million. They reported a net loss of $9.8 million for the quarter.Anavex Life Sciences Financial Statement Overview
Summary
Anavex Life Sciences shows a typical early-stage biotechnology financial profile with no revenue and consistent net losses. However, the balance sheet is strong with no debt, and the company has a good cash position. The financial sustainability depends heavily on future revenue generation from its biotech projects.Income Statement
Anavex Life Sciences has reported zero revenue over the analyzed periods, which is typical for early-stage biotechnology companies that are in the R&D phase. The company experiences consistent net losses, with a TTM net income of -$46.49 million. This indicates a high level of ongoing investment in research without current revenue generation, which is a significant risk factor for financial sustainability.25
Negative
Balance Sheet
The company's balance sheet shows a strong equity position with no debt, resulting in a debt-to-equity ratio of 0. This is a positive indicator of financial stability. However, the return on equity is negative due to ongoing net losses. The equity ratio remains solid, indicating that the company is predominantly financed by equity rather than liabilities.70
Positive
Cash Flow
Anavex Life Sciences demonstrates a negative operating cash flow, reflecting its pre-revenue stage. However, the company has maintained a healthy cash position and has managed to secure financing without taking on debt. The absence of revenue and free cash flow growth underscores the company's reliance on external financing for its operations.60
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -57.73M | 0.00 | 5.29M | -55.76M | -50.94M | -37.38M |
| Net Income | -48.17M | 0.00 | -43.00M | -47.51M | -47.98M | -37.91M |
Balance Sheet | ||||||
| Total Assets | 102.43M | 103.81M | 135.57M | 154.39M | 152.70M | 161.62M |
| Cash, Cash Equivalents and Short-Term Investments | 101.16M | 102.58M | 132.19M | 151.02M | 149.16M | 152.11M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 11.47M | 8.95M | 15.30M | 12.53M | 10.21M | 10.80M |
| Stockholders Equity | 90.96M | 94.87M | 120.26M | 141.85M | 142.49M | 150.82M |
Cash Flow | ||||||
| Free Cash Flow | -37.10M | -39.04M | -30.81M | -27.79M | -24.24M | -30.38M |
| Operating Cash Flow | -37.10M | -39.04M | -30.81M | -27.79M | -24.24M | -30.38M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | -494.00K | 9.43M | 11.97M | 29.65M | 21.29M | 153.24M |
Anavex Life Sciences Technical Analysis
Negative
4.02
Price Trends
6.57
Negative
8.20
Negative
8.62
Negative
Market Momentum
-0.62
Negative
36.45
Neutral
35.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVXL, the sentiment is Negative. The current price of 4.02 is above the 20-day moving average (MA) of 3.84, below the 50-day MA of 6.57, and below the 200-day MA of 8.62, indicating a neutral trend. The MACD of -0.62 indicates Negative momentum. The RSI at 36.45 is Neutral, neither overbought nor oversold. The STOCH value of 35.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AVXL.
Anavex Life Sciences Risk Analysis
Anavex Life Sciences disclosed 52 risk factors in its most recent earnings report. Anavex Life Sciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Anavex Life Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $367.22M | ― | -43.11% | ― | ― | -5.71% | |
55 Neutral | $407.20M | ― | -60.52% | ― | 407.86% | 30.35% | |
54 Neutral | $362.52M | ― | -31.07% | ― | 158.54% | 66.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
40 Underperform | $311.38M | -1.53 | -62.25% | ― | ― | 4.71% | |
40 Underperform | $392.85M | ― | -74.88% | ― | ― | 18.39% | |
35 Underperform | $370.11M | -9.71 | ― | ― | ― | 18.82% |
* Healthcare Sector Average
AVXL
Anavex Life Sciences
4.02
-5.16
-56.21%
GALT
Galectin Therapeutics
6.25
3.94
170.56%
RCKT
Rocket Pharmaceuticals
3.39
-8.37
-71.17%
CLLS
Cellectis SA
4.68
2.95
170.52%
AUTL
Autolus Therapeutics
1.61
-0.97
-37.60%
PEPG
PepGen Inc.
5.66
1.15
25.50%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.